53 related articles for article (PubMed ID: 38734670)
1. Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.
Zhao Y; Laird AD; Roberts KG; Yafawi R; Kantarjian H; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien S; Jabbour E; Cassaday RD; Loyd MR; Olsen S; Neale G; Liu X; Vandendries E; Advani A; Mullighan CG
Blood Adv; 2024 Jun; 8(12):3226-3236. PubMed ID: 38607410
[TBL] [Abstract][Full Text] [Related]
2. Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia.
Brivio E; Bautista F; Zwaan CM
Haematologica; 2024 Jun; 109(6):1700-1712. PubMed ID: 38832425
[TBL] [Abstract][Full Text] [Related]
3. Inotuzumab Ozogamicin: First Pediatric Approval.
Dhillon S
Paediatr Drugs; 2024 May; ():. PubMed ID: 38780741
[TBL] [Abstract][Full Text] [Related]
4. Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens.
Short NJ; Kantarjian H; Jabbour E
Leuk Lymphoma; 2024 Jun; ():1-13. PubMed ID: 38850572
[TBL] [Abstract][Full Text] [Related]
5. Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Gibson A; Nunez C; Robusto L; Kammerer B; Garcia M; Roth M; Sheth R; Tewari P; Hittle A; Toepfer L; Torres R; Short NJ; Jabbour E; Jain N; Cuglievan B; McCall D
Haematologica; 2024 May; ():. PubMed ID: 38779719
[TBL] [Abstract][Full Text] [Related]
6. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions.
Short NJ; Jabbour E; Jain N; Kantarjian H
J Hematol Oncol; 2024 May; 17(1):32. PubMed ID: 38734670
[TBL] [Abstract][Full Text] [Related]
7. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Zhao Y; Short NJ; Kantarjian HM; Chang TC; Ghate PS; Qu C; Macaron W; Jain N; Thakral B; Phillips A; Khoury JD; Garcia-Manero G; Zhang W; Fan Y; Yang H; Garris R; Nasr LF; Kriwacki R; Roberts KG; Konopleva MY; Jabbour EJ; Mullighan CG
Blood; 2024 Mar; ():. PubMed ID: 38551807
[TBL] [Abstract][Full Text] [Related]
8. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia.
Short NJ; Jabbour E; Jamison T; Paul S; Cuglievan B; McCall D; Gibson A; Jain N; Haddad FG; Nasr LF; Marx KR; Rausch C; Savoy JM; Garris R; Ravandi F; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e168-e173. PubMed ID: 38212207
[TBL] [Abstract][Full Text] [Related]
9. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia.
Metheny LL; Sobecks R; Cho C; Fu P; Margevicius S; Wang J; Ciarrone L; Kopp S; Convents RD; Majhail N; Caimi PF; Otegbeye F; Cooper BW; Gallogly M; Malek E; Tomlinson B; Gerds AT; Hamilton B; Giralt S; Perales MA; de Lima M
Blood Adv; 2024 Mar; 8(6):1384-1391. PubMed ID: 38170741
[TBL] [Abstract][Full Text] [Related]
10. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.
Stelljes M; Raffel S; Alakel N; Wäsch R; Kondakci M; Scholl S; Rank A; Hänel M; Spriewald B; Hanoun M; Martin S; Schwab K; Serve H; Reiser L; Knaden J; Pfeifer H; Marx J; Sauer T; Berdel WE; Lenz G; Brüggemann M; Gökbuget N; Wethmar K
J Clin Oncol; 2024 Jan; 42(3):273-282. PubMed ID: 37883727
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
Jabbour E; Haddad FG; Short NJ; Senapati J; Jain N; Sasaki K; Jorgensen J; Wang SA; Alvarado Y; Wang X; DiNardo C; Masarova L; Kadia T; Garris RS; Ravandi F; Kantarjian H
Blood; 2024 Feb; 143(5):417-421. PubMed ID: 37879077
[TBL] [Abstract][Full Text] [Related]
12. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Shah BD; Cassaday RD; Park JH; Houot R; Oluwole OO; Logan AC; Boissel N; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff PJ; Jeyakumar D; Mao D; Adhikary S; Zhou L; Schuberth PC; Damico Khalid R; Ghobadia A
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648261
[TBL] [Abstract][Full Text] [Related]
13. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.
Jabbour E; Short NJ; Senapati J; Jain N; Huang X; Daver N; DiNardo CD; Pemmaraju N; Wierda W; Garcia-Manero G; Montalban Bravo G; Sasaki K; Kadia TM; Khoury J; Wang SA; Haddad FG; Jacob J; Garris R; Ravandi F; Kantarjian HM
Lancet Haematol; 2023 Jun; 10(6):e433-e444. PubMed ID: 37187201
[TBL] [Abstract][Full Text] [Related]
14. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia.
Kantarjian H; Haddad FG; Jain N; Sasaki K; Short NJ; Loghavi S; Kanagal-Shamanna R; Jorgensen J; Khouri I; Kebriaei P; Alvarado Y; Kadia T; Paul S; Garcia-Manero G; Dabaja B; Yilmaz M; Jacob J; Garris R; O'Brien S; Ravandi F; Jabbour E
J Hematol Oncol; 2023 May; 16(1):44. PubMed ID: 37131217
[TBL] [Abstract][Full Text] [Related]
15. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H
J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623
[TBL] [Abstract][Full Text] [Related]
16. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
Rubinstein JD; Breese EH; Krupski MC; O'Brien MM; Dandoy CE; Mizukawa B; Khoury R; Norris RE; Davies SM; Phillips CL
Transplant Cell Ther; 2023 May; 29(5):311.e1-311.e7. PubMed ID: 36809824
[TBL] [Abstract][Full Text] [Related]
17. Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia.
Ceolin V; Brivio E; van Tinteren H; Rheingold SR; Leahy A; Vormoor B; O'Brien MM; Rubinstein JD; Kalwak K; De Moerloose B; Jacoby E; Bader P; López-Duarte M; Goemans BF; Locatelli F; Hoogerbrugge P; Calkoen FG; Zwaan CM
Leukemia; 2023 Jan; 37(1):53-60. PubMed ID: 36310183
[TBL] [Abstract][Full Text] [Related]
18. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.
Jabbour E; Short NJ; Jain N; Thompson PA; Kadia TM; Ferrajoli A; Huang X; Yilmaz M; Alvarado Y; Patel KP; Garcia-Manero G; Macaron W; Garris R; Konopleva M; Ravandi F; Kantarjian H
Lancet Haematol; 2022 Dec; 9(12):e878-e885. PubMed ID: 36279879
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
